Literature DB >> 15742171

Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs.

O S Toungoussova1, A O Mariandyshev, G Bjune, D A Caugant, P Sandven.   

Abstract

Multidrug-resistant tuberculosis has become common all over the world, necessitating the inclusion of second-line drugs in treatment regimens. In the present study, the susceptibility of a selection of multidrug-resistant strains of Mycobacterium tuberculosis isolated in the Archangel oblast, Russia, to second-line anti-tuberculosis drugs was analysed. Susceptibility testing of 77 Mycobacterium tuberculosis strains was performed by the Bactec method using the following recommended drug concentrations: capreomycin 1.25 microg/ml; ethionamide 1.25 microg/ml; kanamycin 5 microg/ml; and ofloxacin 2 microg/ml. The majority of strains (92.2%) were resistant to ethionamide. High rates of drug resistance were also found for capreomycin (42.9%) and kanamycin (41.6%), while nearly all strains (98.7%) were susceptible to ofloxacin. The high rates of resistance to ethionamide, capreomycin, and kanamycin show the real burden of drug resistance in the region and pose a serious problem for the treatment of patients with multidrug-resistant tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15742171     DOI: 10.1007/s10096-005-1284-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Revised international definitions in tuberculosis control.

Authors: 
Journal:  Int J Tuberc Lung Dis       Date:  2001-03       Impact factor: 2.373

2.  Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.

Authors:  G E Pfyffer; D A Bonato; A Ebrahimzadeh; W Gross; J Hotaling; J Kornblum; A Laszlo; G Roberts; M Salfinger; F Wittwer; S Siddiqi
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

3.  Worldwide incidence of multidrug-resistant tuberculosis.

Authors:  Christopher Dye; Marcos A Espinal; Catherine J Watt; Cyrille Mbiaga; Brian G Williams
Journal:  J Infect Dis       Date:  2002-04-01       Impact factor: 5.226

4.  Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates in the Archangel prison in Russia: predominance of the W-Beijing clone family.

Authors:  Olga S Toungoussova; Andrey Mariandyshev; Gunnar Bjune; Per Sandven; Dominique A Caugant
Journal:  Clin Infect Dis       Date:  2003-08-14       Impact factor: 9.079

5.  Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia.

Authors:  Olga S Toungoussova; Per Sandven; Andrey O Mariandyshev; Nina I Nizovtseva; Gunnar Bjune; Dominique A Caugant
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

Review 6.  Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs.

Authors:  R O Laing; K M McGoldrick
Journal:  Int J Tuberc Lung Dis       Date:  2000-12       Impact factor: 2.373

7.  Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia.

Authors:  S Toungoussova; D A Caugant; P Sandven; A O Mariandyshev; G Bjune
Journal:  Int J Tuberc Lung Dis       Date:  2002-05       Impact factor: 2.373

Review 8.  Antimicrobial agent resistance in mycobacteria: molecular genetic insights.

Authors:  J M Musser
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

9.  Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru.

Authors:  Pedro G Suárez; Katherine Floyd; Jaime Portocarrero; Edith Alarcón; Elisabetta Rapiti; Gilbert Ramos; Cesar Bonilla; Ivan Sabogal; Isabel Aranda; Christopher Dye; Mario Raviglione; Marcos A Espinal
Journal:  Lancet       Date:  2002-06-08       Impact factor: 79.321

10.  Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis.

Authors:  Timothy R Sterling; Harold P Lehmann; Thomas R Frieden
Journal:  BMJ       Date:  2003-03-15
  10 in total
  13 in total

1.  Detection of resistance to second-line antituberculosis drugs by use of the genotype MTBDRsl assay: a multicenter evaluation and feasibility study.

Authors:  Olga Ignatyeva; Irina Kontsevaya; Alexander Kovalyov; Yanina Balabanova; Vladislav Nikolayevskyy; Kadri Toit; Anda Dragan; Daniela Maxim; Svetlana Mironova; Tiina Kummik; Ionela Muntean; Ekaterina Koshkarova; Francis Drobniewski
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

2.  TB in immigrants is not public health risk, but uncontrolled epidemics are.

Authors:  Ulf R Dahle
Journal:  BMJ       Date:  2005-07-23

3.  Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.

Authors:  Sabine Rüsch-Gerdes; Gaby E Pfyffer; Manuel Casal; Maureen Chadwick; Salman Siddiqi
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

4.  Evaluation of two molecular assays for rapid detection of mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance Settings.

Authors:  I Kontsevaya; S Mironova; V Nikolayevskyy; Y Balabanova; S Mitchell; F Drobniewski
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

5.  Prevalence of multidrug-resistant and extensively drug-resistant tuberculosis in patients with pulmonary tuberculosis in zahedan, southeastern iran.

Authors:  M Metanat; B Sharifi-Mood; Sh Shahreki; S H Dawoudi
Journal:  Iran Red Crescent Med J       Date:  2012-01-01       Impact factor: 0.611

6.  Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.

Authors:  S B Georghiou; M Seifert; D Catanzaro; R S Garfein; F Valafar; V Crudu; C Rodrigues; T C Victor; A Catanzaro; T C Rodwell
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

7.  Comparative genomic analysis of Mycobacterium tuberculosis drug resistant strains from Russia.

Authors:  Elena N Ilina; Egor A Shitikov; Larisa N Ikryannikova; Dmitry G Alekseev; Dmitri E Kamashev; Maja V Malakhova; Tatjana V Parfenova; Maxim V Afanas'ev; Dmitry S Ischenko; Nikolai A Bazaleev; Tatjana G Smirnova; Elena E Larionova; Larisa N Chernousova; Alexey V Beletsky; Andrei V Mardanov; Nikolai V Ravin; Konstantin G Skryabin; Vadim M Govorun
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

8.  Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010.

Authors:  Sarah E Smith; Julia Ershova; Natalia Vlasova; Elena Nikishova; Irina Tarasova; Platon Eliseev; Andrey O Maryandyshev; Igor G Shemyakin; Ekaterina Kurbatova; J Peter Cegielski
Journal:  Emerg Infect Dis       Date:  2015-06       Impact factor: 6.883

9.  Novel Anthra[1,2-c][1,2,5]Thiadiazole-6,11-Diones as Promising Anticancer Lead Compounds: Biological Evaluation, Characterization & Molecular Targets Determination.

Authors:  Ahmed Atef Ahmed Ali; Yu-Ru Lee; Tsung-Chih Chen; Chun-Liang Chen; Chia-Chung Lee; Chia-Yang Shiau; Chiao-Hsi Chiang; Hsu-Shan Huang
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

10.  Performance of the Genotype MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation.

Authors:  Vladyslav Nikolayevskyy; Yanina Balabanova; Tatyana Simak; Nadezhda Malomanova; Ivan Fedorin; Francis Drobniewski
Journal:  BMC Clin Pathol       Date:  2009-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.